Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Coherus BioSciences, Inc. (CHRS)

6   0 (0%) 03-27 16:00
Open: 6.05 Pre. Close: 6
High: 6.175 Low: 5.965
Volume: 728,754 Market Cap: 478(M)

Technical analysis

as of: 2023-03-27 4:18:10 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 8.11     One year: 9.01
Support: Support1: 5.71    Support2: 4.75
Resistance: Resistance1: 6.94    Resistance2: 7.71
Pivot: 6.28
Moving Average: MA(5): 5.97     MA(20): 6.41
MA(100): 7.56     MA(250): 8.59
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 15.2     %D(3): 14.4
RSI: RSI(14): 36.9
52-week: High: 14.1  Low: 5.58
Average Vol(K): 3-Month: 1,166 (K)  10-Days: 1,118 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CHRS ] has closed above bottom band by 30.9%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.08 - 6.1 6.1 - 6.13
Low: 5.75 - 5.77 5.77 - 5.8
Close: 5.95 - 5.99 5.99 - 6.04

Company Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Headline News

Mon, 13 Mar 2023
Jacobs Levy Equity Management Inc. Sells 316737 Shares of ... - MarketBeat

Sun, 12 Mar 2023
Hsbc Holdings PLC Decreases Holdings in Coherus BioSciences ... - MarketBeat

Wed, 08 Mar 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript - Yahoo Finance

Mon, 06 Mar 2023
After-Hours Earnings Report for March 6, 2023 : TCOM, NTNX ... - Nasdaq

Mon, 06 Mar 2023
FDA Approves UDENYCA® Autoinjector - GlobeNewswire

Mon, 06 Mar 2023
Coherus BioSciences: Q4 Earnings Snapshot - The Associated Press

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 80 (M)
Shares Float 71 (M)
% Held by Insiders 2 (%)
% Held by Institutions 105 (%)
Shares Short 9,840 (K)
Shares Short P.Month 9,540 (K)

Stock Financials

EPS -3
EPS Est Next Qtl -0.76
EPS Est This Year -5.14
EPS Est Next Year -2.62
Book Value (p.s.) -1.75
Profit Margin (%) -138.3
Operating Margin (%) -121.8
Return on Assets (ttm) -27.7
Return on Equity (ttm) 0
Qtrly Rev. Growth -38.3
Gross Profit (p.s.) -0.74
Sales Per Share 2.65
EBITDA (p.s.) -3.19
Qtrly Earnings Growth 0
Operating Cash Flow -241 (M)
Levered Free Cash Flow -191 (M)

Stock Valuations

PE Ratio -2.01
PEG Ratio 0.1
Price to Book value -3.45
Price to Sales 2.26
Price to Cash Flow -1.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.